

2025 MIPS Seminar Program

 15 Oct 2025

 12:00 to 1:00 pm

 LT2

ADVENTURES IN THERAPIES FOR THE DIABETIC HEART

Professor Rebecca Ritchie



Professor Ritchie [FASCEPT, FISHR, FCSANZ; FAHA] is Professor and Head of Drug Discovery Biology (Theme Leader) and Head of Heart Failure Pharmacology in the Monash Institute of Pharmaceutical Sciences (MIPS), Monash University. Prof Ritchie is a cardiac pharmacologist internationally-recognised for her translational research focused on arresting the progression of heart failure. Her career spans discovery, preclinical & clinical research, enabled by long-term collaborations across Monash, the Victorian Heart Institute & the Baker Heart & Diabetes Institute.

Rebecca completed her undergraduate and PhD studies at the University of Adelaide. Her PhD focused on predictors of myocardial function in vivo in patients with ischaemic heart disease, including development of the first quantitative model of the force-interval relationship in human myocardium. Her postdoctoral training — Wayne State University 1995–97, USA and the Florey Institute 1997–2002 — preceded her recruitment to the Baker Heart and Diabetes Institute in late 2002. During her 17 years at the Baker, she was promoted to

lab head (2008), Chair of Science Faculty (2017) and to the institute's Management Round Table (2017). In 2019, she was recruited to Monash University (together with her Heart Failure Pharmacology team) to continue her program of heart failure research, and to lead the Drug Discovery Biology Theme (a head of unit role).

The research achievements of Professor Ritchie to date include >161 publications in leading international journals (>10650 citations, H index 54, GS) and continuous peer-reviewed funding since 1999 (comprising support from NHMRC, MRFF, Diabetes Australia and the Heart Foundation, in addition to industry collaborations including CSL). Her contributions to cardiac pharmacology and to professional scientific organisations are outlined below, and have been recognised by the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT), International Society of Heart Research (ISHR), American Heart Association (AHA), Hypertension Australia, Diabetes Australia, Cardiac Society of Australia and New Zealand (CSANZ) and the British Pharmacology Society (BPS).